MedTrace Logo

MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

NCT00797667 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2018-10-18

Study results available
· View outcomes & findings →

Summary

A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

Conditions

Interventions

DRUG

Telcagepant 140 mg

DRUG

Telcagepant 280 mg

DRUG

140 mg telcagepant placebo

DRUG

280 mg telcagepant placebo

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-12
Primary Completion
2009-05-20
Completion
2009-05-20

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00797667 on ClinicalTrials.gov